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Abstract
Purpose: Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that accounts for approximately 15% of the
newly diagnosed cancers worldwide, and disproportionately affects younger women and women of color. Although many forms
of breast cancer are successfully treated, new therapies are needed for TNBC. A novel regulatory system, the opioid growth
factor (OGF) – opioid growth factor receptor (OGFr) axis, plays a determining role in neoplasia. OGF is an endogenous peptide
that binds specifically to OGFr to inhibit cell replication. As some human cancers grow, OGFr expression is diminished, thus
limiting the therapeutic efficacy of OGF. The OGF-OGFr axis is present in human TNBC cell line MDA-MB-231 and OGF
inhibits cell replication in a dosage-related, receptor-mediated manner. Methods: The present study investigated whether OGFr
protein expression in human breast cancer cell lines grown in vitro or transplanted into nude mice, changed with the stage of
proliferation or size of tumor using western blotting, semi-quantitative immunohistochemistry, and DNA synthesis techniques.
Results: Comparison of log and confluent TNBC cultures revealed that OGF expression was significantly decreased in confluent
cultures relative to levels in log-phase cells. Western blot analyses confirmed that OGFr was reduced in confluent TNBC and
MCF-7 breast cancer cells in comparison to corresponding log-phase cells. Moreover, BrdU labeling was reduced in confluent
cells. Small (<500 mm3) and large (>1000 mm3) TNBC tumors grown in nude mice were processed for semiquantitative
measurement of OGF and OGFr. The expression of both peptide and receptor in large tumors was downregulated relative to
small tumors. Conclusion: The reduced expression of the inhibitory peptide and receptor diminishes the efficacy of the
OGF-OGFr axis as a biotherapy. These data suggest that the OGF-OGFr pathway is altered with cancer progression and one or
more elements of this regulatory pathway may serve as biomarkers for TNBC growth.
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Introduction
Triple negative breast cancer (TNBC) constitutes less than
20% of all cases of invasive breast cancer, but remains the
most aggressive form of breast cancer.1,2 TNBC does not
express the three hormonal receptors estrogen (ER),
progesterone (PR), and human epidermal growth factor
(HER2) that serve as targets for chemotherapy and
immunotherapy for other breast cancers,3,4 thus making it
resistant to many of the viable treatment options available
for breast cancer therapy.2,5-7 The prognosis for successful
treatment and extended survival for women with ER, PR,
and/or HER2 detected in breast tissue approaches 98%,2
whereas the median survival time for patients with TNBC
is 13 months.2,7 TNBC also has an increased prevalence in
younger females, women of color, and those from lower
socioeconomic countries.2 A few studies have reported new
agents to treat TNBC,7-9 but there remains an unmet medical
need to study the underlying biology of TNBC.
Previous studies in our laboratory investigated the presence
and function of a novel biological pathway in TNBC.10 The
opioid growth factor (OGF) – OGF receptor (OGFr) pathway
is present in a wide variety of cancers,11 including TNBC,
and has been shown to modulate neoplasias related to the
female reproductive system.12-16 The OGF-OGFr axis inhibits
the replication of human ovarian cancer cells in culture and
tumor growth in nude mice.12-16 OGF, chemically termed
[Met5]-enkephalin, is a constitutively-expressed
pentapeptide that inhibits cell proliferation by stimulating
the cyclin- dependent inhibitory kinase pathway and
slowing the transition between the G1 and S phases of the
cell cycle.17,18 The mechanism of action of OGF is to inhibit
DNA synthesis by upregulating cyclin-dependent inhibitory
kinases.19 In squamous cell carcinoma of the head and neck,
p16 is upregulated in response to OGF treatment,20 whereas
p21 is upregulated in human pancreatic cancer.21 Other
kinases such as p15 and p18 were not affected by OGF
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exposure. In vitro studies examining two TNBC cell lines,
MDA-MB-231 and BT-20, revealed the presence of both
OGF peptide and OGFr by immunohistochemical staining of
log-phase cells.10 Specificity of peptide and receptor were
confirmed by antibody neutralization and molecular studies
to knockdown classical opioid receptor proteins. OGF
treatment inhibited TNBC cells in a dosage related, receptor
mediated, and reversible manner. Based on siRNA studies,
OGFr was the specific receptor involved in the mediation of
the inhibitory effects of OGF. These data confirmed earlier
studies reporting that the OGF-OGFr axis mediates in vitro
proliferation in MDA-MB-231 and MCF-7 human breast
cancer cell lines, with no changes in growth following OGF
treatment if OGFr expression was reduced.10,11
Analysis of clinical samples from patients with squamous cell
carcinoma of the head and neck  demonstrated that late
stage tumors had markedly fewer OGF receptors relative to
benign margins or normal tonsil tissue based on binding
assays and western blot analyses, suggesting that OGFr
protein expression, but not RNA, became defective as tumor
growth progressed.22 Preclinical studies on human squamous
cell carcinoma of the head and neck inoculated into nude
mice revealed that OGFr expression normalized for protein
was diminished in larger tumors relative to smaller tumors.23
Other clinical studies involving resected ovarian tumors
demonstrated that malignant tissue had significantly less
OGFr expression relative to benign ovarian cysts and ovarian
surface epithelial cells.15 Analysis of tissue samples from cysts
and late stage (III/IV) tumors revealed a decrease in OGF
expression by 29% and 58%, respectively, from normal
cells.15 Expression of OGFr was decreased by 34% and 48%
in cysts and tumors, respectively, relative to normal levels.
Receptor binding assays on cysts and malignant tumor tissues
indicated that tumors had 5.4-fold fewer OGF receptors than
cysts, suggesting that deficits in the OGF-OGFr axis are
amplified as cancer progresses.15
The present study examined the hypothesis that progression
of TNBC may be associated with a decrease in OGFr protein
rendering the tumor tissue less responsive to endogenous or
exogenous OGF treatment. Utilizing both in vitro and in
vivo models of MDA-MB-231 human TNBC, OGFr protein
expression in log and confluent cells, as well as small and
large tumors grown in nude mice, was evaluated by
immunohistochemistry and western blot analyses. For
comparison, human breast cancer cell line MCF-7 that
contains estrogen and progesterone receptors was evaluated
for OGFr expression in log and confluent phases of growth.
Both breast cancer cell lines were treated with OGF to
determine the efficacy of this novel biotherapy in highly
proliferating cells (i.e., log phase) and in a setting of reduced
replication (i.e., confluence).
Methods and Materials
Cell culture and cell growth assays
The human breast cancer lines MDA-MB-231 and MCF-7
were purchased and verified by The American Type Culture
Collection (Manassas, VA). MDA-MB-231 cells lack
estrogen, progesterone, and human epidermal growth factor
receptor 2 (HER2) receptors, designating these cells as a
TNBC cell line.1 This cell line is derived from a 51-year-old
female with metastatic breast cancer. MCF-7 cells were
derived from a 69-year-old Caucasian female and
characterized at the Michigan Cancer Foundation to contain
estrogen and progesterone receptors.24 MDA-MB-231 cells
were grown in Leibovitz L-15 medium supplemented with 2
mM L-glutamine, and MCF-7 cells were cultured in
Dulbecco’s modified Eagle’s medium. All media were
supplemented with 10% fetal calf serum, 1.2% sodium
bicarbonate, and antibiotics (5,000 Units/ml penicillin, 5
mg/ml streptomycin). Cells were maintained in a humidified
atmosphere of 5% CO2 at 37oC.
For growth assays, cells were plated in 24-well plates and
counted 24 hours later (time 0) to determine seeding
efficiency. In some assays, 10-6 M OGF or sterile water
(equivalent volume, 1 µl) was added at time 0; media and
compounds were changed daily.12 All drugs were prepared in
sterile water and dilutions represent final concentrations.
Cells were harvested at designated times and counted by
hemacytometer using trypan blue exclusion methodology. At
least two aliquots per well from two wells/treatment at each
time point were sampled.
Animals and tumor growth
Female 4- to 5-week old athymic nu/nu mice were
purchased from Charles River Laboratories (Wilmington,
MA) and housed in pathogen-free isolators in a controlled
-temperature room (22-25oC) with a 12/12 hour light/dark
cycle. Sterile rodent diet and water were available ad
libitum. All procedures were approved by the IACUC
committee of the Pennsylvania State University College of
Medicine. Following a 48 hour acclimation period,
unanesthetized mice were inoculated subcutaneously in the
right scapular and left flank regions with MDA-MB-231 cells
(8 × 106 cells/0.1 ml per injection). Mice were weighed
weekly and observed daily for the appearance of tumors.
Individual tumors were measured three times/week using a
digital vernier caliper and volumes calculated as previously
described.13,23,25
Tissue collection
Tumors were harvested as small or large when the tumor
volume reached approximately 350 mm3 or 1000 mm3,
respectively. Tumor bearing mice were euthanized with an
injection (0.1 ml/mouse) of Euthasol (Virbac AH, Inc, Fort
Worth, TX) followed by cervical dislocation; the body cavity
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was examined for metastases.13,16 Tumor tissue was either
frozen in isopentane chilled on dry ice for
immunohistochemistry or placed in RIPA buffer and stored
at -20o C for western blotting protein assays.16 All tissues
were processed within 2 weeks of collection.
Immunohistochemistry
The presence and quantity of OGF and OGFr were evaluated
in both cells and tumor tissue following published
protocols.10,11,16 Log-phase (104 cells/well) and super
confluent (106 cells/well) MDA-MB-231 and MCF-7 cells
were seeded onto 22 × 22 mm glass coverslips in 6-well
plates. After 72 hours in culture the cells were fixed and
permeabilized in 95% ethanol and acetone at -20oC, rinsed
in Sorenson’s phosphate buffer (SPB), and blocked with SPB
containing 1% normal goat serum and 0.1% Triton-X 100 at
room temperature for 15 min. Cells were stained 1:200 with
anti-OGF-IgG (CO172) and anti-OGFr-IgG (BO344)
polyclonal antibodies diluted in SPB containing 1% normal
goat serum and 0.1% Triton-X 100 for 2 hours at room
temperature, followed by secondary goat anti-rabbit IgG
antibodies (1:1000) for 45 min.16,25 Cells incubated with
secondary antibody only were considered controls.
Tumor tissue was cryosectioned (10 µm) and stained as
described previously with primary antibody for 18 hours at
room temperature, followed by secondary antibody.12,13,15
Mean intensity of positively stained tumor cells was
determined from at least 8 fields per coverslip and 3
coverslips/group.12 With regard to tumors, random samples
of 3 fields/section from 6 sections/tumor and 2 tumors/group
were assessed.13,15 All specimens were visualized with an
Olympus IX-81 epifluorescence microscope.
Protein isolation and western blotting
OGFr expression levels were evaluated in cells and tumor
tissue by western blotting.10, 12-15 Cells were sheared 3-4 times
with a 25 gauge needle while tumor tissue was homogenized
in RIPA buffer containing PMSF protease inhibitors. Equal
amounts of protein (40 µg) were subjected to SDS
polyacrylamide gel electrophoresis; nitrocellulose
membranes were probed with goat polyclonal IgG antibody
to OGFr (1:500) and donkey anti-goat IgG antibody (1:8000).
Densitometric assessment of bands was normalized to
GAPDH.
DNA synthesis
OGF inhibition of DNA synthesis was evaluated in cell
culture using 5-bromo-2’-deoxyuridine (BrdU)
incorporation. Log-phase and confluent MDA-MB-231 and
MCF-7 cells were seeded onto 22 × 22 mm glass coverslips in
6-well plates and treated with 0.2 µl OGF or sterile saline
daily for 72 hours; media and drugs were changed daily.
Three hours prior to fixation, 30 mM BrdU (Sigma
Chemicals, Indianapolis, IN) was added to each well. Cells
were rinsed, fixed in 1:1 methanol acetone for 20 min at 4oC,
and stained with anti-BrdU mouse monoclonal antibody
(1:200). At least 1000 cells/treatment from 2-4
coverslips/treatment were counted. Labeling indexes were
calculated as the number of positively stained cells divided
by the total number of cells.
Data analyses
All data were analyzed using two-tailed Student’s t-test for
two groups, or analysis of variance with subsequent
comparisons made with Newman-Keuls tests for multi-group
comparisons. All analyses were conducted with GraphPad
Prism 5 software (GraphPad Inc, San Diego, CA). P-values
less than 0.05 were considered statistically significant.
Results
Presence and relative expression of OGF and OGFr in
human breast cancer cells
MDA-MB-231 TNBC cells grown to either log phase or
confluency were stained with OGF and OGFr antibodies
(Figure 1A).  Semi-quantitative densitometric assessment of
peptide and receptor expression revealed a 22% decline in
receptor expression (anti-BO344) and a 10% reduction in
OGF (anti-CO172) peptide staining in confluent cell cultures
relative to expression levels in log-phase cells (Figure 1B).
However, exogenous OGF treatment of log-phase
MDA-MB-231 cells exhibited significant reductions in cell
number after 72 and 96 hours of peptide exposure relative to
sterile water-treated cells, suggesting that the OGF-OGFr
axis was functional in TNBC (Figure 1C).
For comparison, MCF-7 human breast cancer cells
containing estrogen and progesterone receptors were grown
to log phase and confluency, and immunostained with
anti-OGF and anti-OGFr antibodies (Figure 2A). Assessment
of peptide and receptor expression in these breast cancer
cells revealed a 33% reduction in receptor and 29%
reduction in peptide levels in confluent cultures relative to
log-phase cells (Figure 2B). Exogenous treatment of
log-phase MCF-7 cells with OGF demonstrated growth
inhibition at 48 and 72 hours relative to cells treated with
sterile water (Figure 2C), suggesting that the OGFr was
intact and functioning.
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FIG. 1: The presence and function of the OGF-OGFr axis in human triple negative breast cancer cells. (A) Expression of OGF and OGFr in
log-phase and confluent MDA-MB-231 cells as detected by immunocytochemistry. Cultures were stained with antibodies to OGF (CO172,
1:200) or OGFr (BO344, 1:200); cells stained with secondary antibody served as controls; (B) Data (mean ± SEM) represent the mean intensity of
TRITC staining with BO344 and CO172 and were analyzed individually using t-tests. Significantly different from respective log-phase cells at
***P < 0.001 and **P < 0.01; (C) OGF inhibition of cells growth. MDA-MB-231 cells were treated with 10-6 M OGF or sterile water. Cells were
counted at 24, 48, 72, and 96 hours. Data represent means ± SEM for triplicate samples. Significantly different from control time points at
**P < 0.01 or ***P < 0.001.
FIG. 2: The presence and function of the OGF-OGFr axis in MCF-7 human breast cancer cells. (A) Expression of OGF and OGFr in log-phase
and confluent MCF-7 cells as determined by immunocytochemistry. Cultures were stained with antibodies to OGF (CO172, 1:200) or OGFr
(BO344, 1:200); cells stained with secondary antibody only served as controls; (B) Data (mean ± SEM) represent the mean intensity of TRITC
with BO344 and CO172 and were analyzed individually using t-tests. Log-phase cells significantly different from confluent cells at ***P < 0.001;
(C) OGF inhibition of cell growth. MCF-7 cells were treated with 10-6 M OGF or sterile water. Cells were counted at 24, 48, or 72 hours. Data
represent means ± SEM for triplicate samples. Significantly different from control time points at ***P < 0.001.
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FIG. 3: Western blots of OGFr protein expression in MDA-MB-231 human TNBC and MCF-7 breast cancer cells. Histograms represent
densitometric ratios of OGFr/GAPDH (means ± SEM) from 3 blots. OGFr expression differs from log-phase and confluent cells at *P < 0.05 or **P
< 0.01.
Imaging of the immunocytochemical preparations revealed
that the cellular distribution patterns of OGF and OGFr
within the cancer cells were comparable for both breast
cancer cell lines.
Protein expression of OGFr as evaluated by western blot
analysis, and normalized to GAPDH, revealed that receptor
expression was markedly diminished in confluent cells
relative to log-phase cultures (Figure 3). Nuclear
homogenates of log-phase and confluent cultures of both
MDA-MB-231 TNBC and MCF-7 breast cancer cells also
displayed a significant decrease in receptor expression in
confluent cultures in comparison to those values from
log-phase cells. Confluent TNBC cells had a 50% reduction
in receptor expression relative to log-phase cells, whereas
confluent MCF-7 cells had 86% less expression of OGFr in
comparison to log-phase cells.
DNA synthesis rates in log phase and confluent
cultures of TNBC or MCF-7 breast cancer cells
To evaluate whether the mechanism underlying the
inhibitory effects of OGF was altered, DNA synthesis as
measured by BrdU incorporation was assessed in log and
confluent cultures treated with OGF or sterile water
(controls). In control cultures of both TNBC (Figure 4A) and
MCF-7 human breast cancer (Figure 4B), BrdU incorporation
was greatest in log-phase cells relative to confluent cultures.
OGF-treated log and confluent phase MDA-MB-231 TNBC
cells exhibited a 44% and 29.8% decrease, respectively, in
BrdU incorporation relative to control treated TNBC cells;
these reductions in DNA synthesis were comparable.
Evaluation of cultures of MCF7 breast cancer cells treated
with OGF revealed a 30% decline in DNA synthesis in
log-phase cells, and a 77% reduction in BrdU incorporation
in confluent cultures relative to that recorded in
sterile-water treated confluent cultures (Figure 4).
Calculation of OGF inhibition of growth over a 72-hour
period of time revealed that log-phase MDA-MB-231 cells
were inhibited 35% relative to controls. In comparison,
growth of confluent TNBC cells was reduced approximately
15%. Reductions in cell replication of log-phase MCF-7 cells
ranged between 28 and 32% relative to 12% reductions in
confluent cells following OGF treatment. These data suggest
that confluent cells are less responsive to OGF treatment
than log-phase cells, supporting the integral role of OGFr to
mediate growth inhibition by OGF.
FIG. 4: The inhibitory effect of OGF on DNA synthesis. MDA-MB-231 cells (A) and MCF-7 cells (B) were seeded on 22 mm coverslips and
treated for 3 hr with OGF (10-6 M) or sterile water (control) and 30 um BrdU. Data (mean ± SEM) represent the percent of BrdU-positive cells.
Significantly different from respective control treated cells at **P < 0.01 or ***P < 0.001, and from respective log-phase cells at +P < 0.05,
++P < 0.01, or +++P < 0.001.
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FIG. 5: The presence of the OGF-OGFr axis in nude mouse tumors of human breast cancer as determined by immunocytochemistry. (A) Large
and small tumor volumes differed significantly at **P < 0.01; (B, C) Differential expression of OGF and OGFr in large and small tumors is
detected by immunohistochemical staining (C) and semi-quantiative analyses. Tumors were sectioned and stained with antibodies to OGFr
(BO344, 1:200) and OGF (CO172, 1:200); sections stained with secondary antibody only served as controls. (A) Data (mean ± SEM) represent
mean intensity of TRITC with BO344 (OGFr) and CO172 (OGF). Large tumors differed significantly from respective small tumors at **P < 0.01
using two-tailed t-test analyses. (D) Western blots of OGFr protein expression in small and large tumors; GAPDH staining served to control for
protein load. Histogram represents the densitometric ratio (means ± SEM) from 3 blots. OGFr expression differed significantly between small
and large tumors at ***P < 0.001.
TNBC tumor growth in nude mice
Female athymic nude mice weighed approximately 20 g at
the beginning of experimentation, and no differences in
body weight were noted in mice with small or large tumors
at the time of termination. No metastases were noted. Tumor
weight and tumor volume of small and large TNBC tumors
differed significantly (Figure 5A). Tumor volumes were less
than 500 mm3 for small tumors whereas large tumors were
greater than 1000 mm3.
OGFr immunolabeling was detected in the cytoplasm and
nucleus of specimens from small and large TNBC tumors
(Figure 5B, C); no immunoreactivity could be observed in
sections processed with secondary antibody only.
Semi-quantitative densitometry revealed that receptor
expression was reduced 37% in the large tumors, and 15%
for OGF peptide expression, relative to small tumors (Figure
5C).
Isolated OGFr protein was evaluated by western blot
analyses and was reduced by 50% in large tumors relative to
small tumors (Figure 5D).
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Discussion
These studies are the first to report that the presence of the
OGF-OGFr regulatory axis in TNBC provides a novel
pathway for controlling the progression of neoplasia, and
that OGFr expression is downregulated as TNBC cells
become confluent or tumors grow larger. Together these
data support and extend our observations that an intact
OGF-OGFr pathway plays an active role in modulation of
neoplasia, and that OGFr is required for modulating tumor
growth by the inhibitory peptide OGF.10-15
Several lines of investigation support this hypothesis.
Utilizing comparison between log-phase highly proliferative
cells and those that are confluent, OGFr expression in two
human breast cancer cell lines was markedly reduced in
confluent cells, suggesting that as neoplastic cells become
more differentiated, the receptor protein is downregulated in
both immunostaining and western blotting. Secondly, in
culture, endogenous OGFr expression is reduced in confluent
cells relative to log-phase TNBC or MCF-7 cells. Although
OGF continued to be effective at suppressing replication
suggesting that the remaining OGFr receptors were
functional, the magnitude of growth inhibition by OGF was
reduced in confluent cultures relative to that in log-phase
cells. Levels of DNA synthesis as measured by BrdU
incorporation confirmed this observation.
In vivo comparison of small and large tumors, which is not
completely analogous to human cancer growth, but does
provide a model for comparison within a reasonable period
of time, confirmed and extended the tissue culture
observations. OGF and OGFr expression was diminished
relative to that recorded in log-phase cells and small tumors.
Up to 50% reductions in receptor expression were recorded.
Using tumors that were generally 2-fold greater in diameter
and volume for comparison, small tumors contained OGF
receptors that had 2-fold more receptors than large tumors.
Likewise, evaluation of the MCF-7 breast cancer cell line
that contains estrogen and progesterone receptors, revealed
the loss of OGFr expression in confluent cultures relative to
log-phase cells.
Given that TNBC is an aggressively growing breast cancer,
the downregulation of a regulatory pathway in advanced
stage tumors may serve as a potential biomarker for cancer
progression and response to therapy.
OGFr must be present for exogenous biotherapy (i.e., OGF
infusion) to be effective. The specific receptor modulating
the inhibitory effects of OGF is reported to be OGFr,28 and
breakdown or loss of the receptor limits the inhibitory
efficacy of OGF.11,14 Disruption of the OGF-OGFr axis in
human cancer cell lines by continuous exposure to an opioid
antagonist, neutralization of endogenous opioids, or
knockdown of the OGFr stimulates DNA synthesis.3-5 Thus
biological loss of the receptor in advanced stages of neoplasia
would be detrimental for natural regulation by endogenous
opioids such as OGF.
Previous research has documented the presence of the
OGF-OGFr axis in a wide variety of human cancers,
including pancreatic, colon, renal, ovarian, neuroblastoma,
hepatocellular adenoma, SCCHN, and breast.11,17 These data
for TNBC are comparable to that reported for squamous cell
carcinoma of the head and neck (SCCHN). In an earlier
study in nude mice, small sized SCCHN tumors had 3- to
7-fold more OGFr than large tumors. However, binding
affinity of receptors from small or large tumors were
unchanged in the SCCHN tumors.23 Disruption of the
OGF-OGFr pathway can occur by disease, genetic mutation,
continuous exposure to opioid antagonists, neutralization of
endogenous opioids, or other imbalances that can accelerate
neoplastic cell growth.17 Conversely, upregulation of the
OGF-OGFr axis has been shown to repress cell division in
both normal and abnormal cells.26,27
TNBC has received minimal attention for specific treatment
modalities targeting its unique biology. Most current
approaches are still in the preclinical stage,28 but warrant
follow-up trials. The clinical significance of data in this
report lies in the fact that OGF is an endogenous opioid that
can be safely infused for therapy. Moreover, low dosages of
naltrexone (LDN) provide a second approach for
upregulating the OGF-OGFr axis in TNBC patients. LDN is
an oral medication that has been shown to be safe over long
periods of time for treatment of autoimmune diseases.29
However, preclinical studies with LDN and human breast
cancer cell lines10 remain promising for the role of the
OGF-OGFr axis in modulation of TNBC. In all cases, OGFr is
the specific receptor mediating the inhibitory growth effects
of OGF or LDN. Loss of function related to defective or
downregulated protein expression of OGFr would render
these therapies ineffective. Knowledge of this biomarker
may be useful for individualized patient therapy of TNBC.
Conclusion
TNBC accounts for approximately 15% of all cases of
invasive breast cancer, but does not respond to most current
therapies.6,7 TNBC frequently affects younger women and
women of color, and is characterized by a high tendency to
metastasize outside the breast.7,8 Despite a better than 98%
five-year relative survival rate for women with successfully
treated breast cancer containing estrogen and progesterone
receptors, the median survival rate for patients with
metastatic TNBC is only 13 months.7 There is an unmet
medical need to develop novel treatments that target
underlying biology of tumor growth. These data confirm
that OGF can be used to inhibit the proliferation of human
TNBC, as well as other breast cancers in vitro, demonstrating
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the potential of the OGF-OGFr pathway as a successful
biological therapy for treatment of TNBC.
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